2007: RA Treatment: Novel Targets, Mechanisms of Action and Predictors of Response

RA Treatment: Novel Targets, Mechanisms of Action and Predictors of Response

Saturday, November 10, 2007

1769

TNF-α Knockdown Using Polymeric/siRNA Nanoparticles as a Treatment Strategy for Collagen Type II Induced Arthritis in Mice

1770

Bim-BH3 Peptide Mimetic Therapy is Effective at Preventing Development of Inflammatory Arthritis

1771

Efficacy and Tolerability of Novel JAK inhibitors in Animal Models of Rheumatoid Arthritis

1772

Antagonism of the P2X₇ Receptor Attenuates Joint Destruction in a Model of Arthritis

1773

Parthenolide Ameliorates the Arthritis and Joint Destruction in the Murine Model of Rheumatoid Arthritis

1774

Methotrexate (MTX) Exerts Anti-atherogenic Effects on Cholesterol Efflux from Monocytes/Macrophages via Activation of the Adenosine A2A Receptor

1775

Downregulation of Macrophage Migration Inhibitory Factor (MIF) By Anti-TNF-Therapy in Rheumatoid Arthritis Patients

1776

TWEAK and TWEAK Ligand/FN14 Expression in Rheumatoid Arthritis Synovial Tissue and Clinical Response to TNF Blockade

1777

Anti-Tumor Necrosis Factor Therapy in Rheumatoid Arthritis Alters CD80 Expression on B-Lymphocytes

1778

Anti-Inflammatory Effects of a Novel Class of 5-HT2 Receptor Binding Compounds

1779

Characterization of Anti-arthritic Effect of a Novel Small Molecule AP-1 Inhibitor T-5224.

1780

Resveratrol Induces the Apoptosis in Synovial Fibroblasts of Rheumatoid Arthritis

1781

Tacrolimus Overcomes Treatment-Unresponsiveness Mediated by P-glycoprotein on Lymphocytes in Refractory Rheumatoid Arthritis

1782

Interferon Gamma Decreases Interleukin 1β Mediated Cartilage Loss in Rheumatoid Arthritis by Inhibiting MMP Production

1783

Epigallocatechin-3-gallate (EGCG) Downregulates PGE₂ Mediated Production of Interleukin-6 (IL-6) in Rheumatoid Arthritis Synovial Fibroblasts

1784

Rheumatoid Arthritis Synovial T Cells are Resistant to Glucocorticoid Induced Apoptosis

1785

In Untreated, Active, Early Rheumatoid Arthritis Up-regulated Density Of CCR7 On Monocytes And CD4+ T-lymphocytes Is Differentially Influenced By Clinically Effective Dmard: The CCR7 Density On Monocytes Is Normalized But It Remains Up-regulated On CD4+ T

1786

In Untreated, Active, Early Rheumatoid Arthritis Patients CD26 Density on Monocytes and CD4+ Lymphocytes Correlate to CRP and DAS28 and on Monocytes the CD26 Density was Unaffected by a Clinically, Effective DMARD Treatment

1787

CF502 Targets the A₃ Adenosine Receptor to Induce Anti-Inflammatory Effect Via Down-Regulation of the NF-KappaB Signaling Pathway

1788

Anti-Rheumatic Effect of ZSTK474, a Novel Phosphoinositide 3-kinase Inhibitor, by Inhibiting Osteoclast Formation

1789

Microparticles in Peripheral Blood Decrease in Patients with Active Rheumatoid Arthritis by Leukocytapheresis

1790

Inhibitory Effects of Melittin on the Production of Lipopolysaccaharide-induced Matrixmetalloproteinase 3 in Human Rheumatoid Arthritic Fibroblast Like Synoviocytes

1791

Effects of Hormone Replacement Therapy on Resistin in Rheumatoid Arthritis

1792

Simvastatin Inhibits Production of Pentraxin 3 and Monocyte Chemoattractant Protein-1 in Fibroblast-Like Synoviocytes from Patients with Rheumatoid Arthritis

1793

Preparation of a TAT-PTD CDKI Fusion Protein that efficiently Inhibits Proliferation and MMP-3 Production of Rheumatoid Synovial Fibroblasts

1794

Differential Peripheral Blood Gene Expression Profile of Rheumatoid Arthritis in Response to Anti-TNF Treatment

1795

Genotypes Coding for High-Affinity Variants of Fc Gamma Receptors IIA (CD32A) y IIIA (CD16A) are Associated with Poorer ACR Response to Therapy with Infliximab in Patients with Rheumatoid Arthritis

1796

Global Gene Expression Profiles in the Synovium of Rheumatoid Arthritis Patients Treated with Adalimumab

1797

Anti-cyclic Citrullinated Peptide Antibodies and High Il-15 Serum Levels are Better Predictors than Rheumatoid Factor for Intensive Treatment in Early Arthritis Patients

1798

Utilization of Host Resistance Models (HRMs) in the Prediction of Human Safety of Abatacept (ABA): A Translational Approach

1799

Influence of Genetic Variation in the TNF, LTA and LST-1 Genes on the Response to Treatment of Rheumatoid Arthritis with Anti-TNF Therapy in a Large Cohort of UK Patients

1800

HLG-G 14bp Polymorphisms Are Not Associated with Methotrexate Response in Rheumatoid Arthritis

1801

Synovial Markers of Response to Adalimumab in Severe Rheumatoid Arthritis

1802

An In Silico Model of Rheumatoid Arthritis Predicts Key Pathways of Bone Erosion and Candidate Biomarkers of Therapeutic Efficacy

1803

Remission of Rheumatoid Arthritis is Predicted by Baseline Variables Including Low Disease Activity, Less Joint Damage, and Better Physical Function

1804

High Remission During Treatment of Patients with Early Rheumatoid Arthritis by Monitoring with DAS28 or a Biochemical Marker of Cartilage Degradation, CTX-II: A Pilot Study

1805

Biologic Drugs Targeting the TNF-α and IL-6 Pathways Induces Fibroblast-like Synoviocytes Apoptosis

See more of: ACR Abstract Submission Poster Sessions

<< Previous Session Level | Next Session Level >>